查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1864671

分子診斷自動化市場按產品類型、最終用戶、技術、自動化程度和應用分類－2025-2032年全球預測

Automation in the Molecular Diagnostics Market by Product Type, End User, Technology, Automation Level, Application - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，分子診斷自動化市場規模將達到 454.2 億美元，複合年成長率為 16.33%。

關鍵市場統計數據
基準年 2024 135.4億美元
預計年份：2025年 157.8億美元
預測年份 2032 454.2億美元
複合年成長率 (%) 16.33%

分子診斷自動化如何重塑臨床和研究環境中的檢查室工作流程、品質預期和策略重點

對於分子診斷檢查室，自動化不再是漸進式改進，而是影響臨床吞吐量、資料完整性和營運韌性的策略要務。機器人技術、整合檢體處理和雲端數據分析的進步正與不斷變化的臨床需求相融合，共同創造出一個檢查室能夠減少人工操作時間、標準化通訊協定並提供更快、更可重複結果的環境。因此，自動化不僅影響日常營運，也影響資本投資規劃、人才培育和供應商選擇。

分子診斷領域正經歷著由整合自動化、互通軟體以及不斷變化的臨床和營運需求所驅動的重大變革。

分子診斷領域正經歷變革性的轉變，這主要得益於技術的成熟、工作流程的整合以及不斷變化的臨床需求。定序平台和高通量PCR系統與微陣列解決方案以及從樣本到結果的先進數據分析工具相輔相成，使檢查室能夠擴展檢測項目並縮短週轉時間。同時，軟體編配和雲端基礎的分析技術也使得複雜的多儀器工作流程的管理更加透明和審核。

評估不斷變化的美國關稅政策對診斷設備製造商和檢查室的採購、供應鏈韌性和策略採購決策的影響

美國近期關稅政策的變化和貿易政策的調整正在影響分子診斷設備、耗材和軟體的採購和供應動態。實驗室和診斷設備供應商面臨著不斷變化的成本結構，這影響著他們的採購選擇、庫存策略和合約談判。隨著關稅改變進口零件和成品的相對經濟效益，各機構正在重新評估其供應商佈局，並考慮其他製造地和本地庫存策略，以降低風險並維持醫療服務的連續性。

全面的細分分析重點闡述了產品類型、最終用戶、技術、自動化等級和應用如何驅動產品採用、價值和供應商策略。

細分分析揭示了產品類型、最終用戶、技術、自動化程度和應用領域如何影響診斷生態系統的採用模式和價值實現。根據產品類型，產品範圍涵蓋耗材和試劑（例如，微陣列晶片、次世代定序樣品製備盒和PCR試劑盒）、儀器（例如，微陣列系統、NGS儀器和PCR儀器），以及軟體和服務（包括數據分析平台、整合服務和管理服務）。這些類別相互影響：儀器的普及推動了對耗材的持續需求，而軟體和服務則實現了高價值的應用場景和營運擴充性。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 將高通量自動化技術整合到次世代定序流程中，可以縮短週轉時間。
  • 在分散式診斷實驗室中實施用於多重PCR檢測的機器人樣本製備平台
  • 實施人工智慧驅動的數據分析流程，用於即時解讀分子診斷結果
  • 開發用於偏遠地區照護現場核酸檢測的模組化實驗室晶片設備
  • 標準化自動化液體處理通訊協定，以提高多站點分子檢測網路的可重複性
  • 擴展的封閉式自動化系統結合了樣本提取和qPCR技術，以最大限度地降低污染風險和操作人員誤差。

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 按產品類型分類的分子診斷自動化市場

  • 耗材和試劑
    • 微陣列晶片
    • 次世代定序樣品製備盒
    • PCR試劑盒
  • 裝置
    • 微陣列系統
    • 次世代定序設備
    • PCR設備
  • 軟體和服務
    • 數據分析軟體
    • 整合服務
    • 託管服務

9. 按最終用戶分類的分子診斷自動化市場

  • 臨床實驗室
  • 醫院實驗室
  • 製藥和生物技術公司
  • 參考實驗室
  • 研究實驗室

第10章 依技術分類的分子診斷自動化市場

  • 微陣列
  • 次世代定序（NGS）
  • PCR

第11章 分子診斷自動化市場（依自動化程度分類）

  • 全自動系統
  • 半自動系統
  • 無人值守自動化

第12章：按應用分類的分子診斷自動化市場

  • 心血管疾病
  • 基因檢測
  • 感染疾病
  • 腫瘤學
  • 女性健康

第13章 各地區分子診斷自動化市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 分子診斷自動化市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國分子診斷自動化市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • F. Hoffmann-La Roche Ltd
    • Thermo Fisher Scientific Inc.
    • Danaher Corporation
    • Abbott Laboratories
    • QIAGEN NV
    • bioMerieux SA
    • Bio-Rad Laboratories, Inc.
    • Siemens Healthineers AG
    • PerkinElmer, Inc.
    • Agilent Technologies, Inc.
Product Code: MRR-2D1F5C65740B

The Automation in the Molecular Diagnostics Market is projected to grow by USD 45.42 billion at a CAGR of 16.33% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 13.54 billion
Estimated Year [2025] USD 15.78 billion
Forecast Year [2032] USD 45.42 billion
CAGR (%) 16.33%

How automation in molecular diagnostics is redefining laboratory workflows, quality expectations, and strategic priorities across clinical and research environments

Automation is no longer an incremental improvement for molecular diagnostics laboratories; it has become a strategic imperative that affects clinical throughput, data integrity, and operational resilience. Advances in robotics, integrated sample processing, and cloud-enabled data analysis are converging with evolving clinical needs to create a landscape where laboratories can reduce hands-on time, standardize protocols, and deliver faster, more reproducible results. As a result, automation influences not only day-to-day operations but also capital planning, workforce development, and vendor selection.

Moreover, the drivers of automation extend beyond simple efficiency gains. Regulatory expectations for traceability and quality, the need to scale testing during infectious disease surges, and the demand for complex genomic assays in oncology and hereditary disease testing all push laboratories toward higher degrees of automation. In turn, suppliers respond with modular architectures, scalable software platforms, and expanded service models. Consequently, stakeholders must view automation as a systems-level change that intersects with clinical strategy, IT infrastructure, and supply chain management.

Key transformative shifts in the molecular diagnostics landscape driven by integrated automation, interoperable software, and evolving clinical and operational demands

The molecular diagnostics landscape is experiencing transformative shifts driven by technology maturation, workflow integration, and changing clinical demand. Sequencing platforms and high-throughput PCR systems now coexist with sample-to-answer microarray solutions and sophisticated data analysis tools, enabling laboratories to broaden their test menus and reduce turnaround times. At the same time, software-enabled orchestration and cloud-based analytics are making it feasible to manage complex multi-instrument workflows with greater transparency and auditability.

Transitioning from fragmented instrument fleets to integrated automation ecosystems also alters procurement approaches and vendor relationships. Suppliers that deliver interoperability, validated workflows, and long-term service agreements gain strategic advantage. Meanwhile, laboratories prioritize solutions that reduce manual interventions, limit contamination risk, and enable remote monitoring. Taken together, these shifts are driving consolidation of point technologies into end-to-end solutions, aligning technical innovation with clinical and operational imperatives.

Assessing how evolving United States tariff policies influence procurement, supply chain resilience, and strategic sourcing decisions across diagnostics manufacturers and laboratories

Recent tariff developments and trade policy changes in the United States have influenced the procurement and supply dynamics for molecular diagnostics equipment, consumables, and software. Laboratories and diagnostic suppliers face an evolving cost structure that affects sourcing choices, inventory strategies, and contractual negotiations. As tariffs alter the relative economics of imported components and finished products, organizations reassess supplier footprints and consider alternative manufacturing locations or local stocking strategies to mitigate exposure and preserve continuity of care.

In response to these trade-induced pressures, industry participants increasingly emphasize supplier diversification and nearshoring. Procurement teams work to redesign contracts with clearer clauses for tariffs, duties, and lead-time variability while supply chain teams collaborate with logistics partners to maintain buffer inventories without sacrificing cold-chain integrity. Concurrently, manufacturers respond by optimizing bill-of-materials, qualifying alternate suppliers, and in some cases accelerating regional manufacturing investments. The cumulative effect reshapes commercial conversations around pricing transparency, service commitments, and risk-sharing arrangements, prompting both buyers and sellers to adopt more resilient, collaborative procurement models.

Comprehensive segmentation insights highlighting how product categories, end users, technologies, automation levels, and applications determine adoption, value, and vendor strategies

Segmentation analysis reveals how product type, end user, technology, automation level, and application areas shape adoption patterns and value realization across the diagnostics ecosystem. Based on product type, offerings range from consumables and reagents-encompassing microarray chips, next-generation sequencing library preparation kits, and PCR kits-to instruments such as microarray systems, NGS instruments, and PCR instruments, as well as software and services that include data analysis platforms, integration services, and managed services. These categories interact: instrument adoption often drives recurring consumable demand while software and services facilitate higher-value use cases and operational scalability.

Based on end user, adoption trajectories diverge among clinical laboratories, hospital laboratories, pharmaceutical and biotechnology companies, reference laboratories, and research laboratories. Each segment prioritizes different performance attributes: clinical laboratories emphasize throughput and regulatory compliance, hospital labs focus on rapid turnaround for patient care, pharmaceutical and biotech customers seek scalability for drug development workflows, reference laboratories value consolidation and automation economies, and research labs often prioritize flexibility and cutting-edge capabilities. Based on technology, choices center on microarrays, NGS, and PCR, with each modality offering distinct trade-offs in sensitivity, resolution, and workflow complexity. Automation level further stratifies the landscape into fully automated systems, semi-automated systems, and walkaway automation, each balancing capital intensity against labor savings. Finally, application areas such as cardiovascular disease screening, genetic testing, infectious disease diagnostics, oncology, and women's health create specialized requirements for sample throughput, assay validation, and data interpretation. By synthesizing these segmentation axes, stakeholders can align product roadmaps, service offerings, and commercialization strategies with the differentiated needs of laboratory segments and clinical applications.

Regional insights illustrating how distinct clinical infrastructure, procurement practices, and regulatory environments in the Americas, EMEA, and Asia-Pacific shape automation adoption and commercialization

Regional dynamics shape technology adoption, reimbursement pathways, and supply chain priorities across the molecular diagnostics landscape. In the Americas, advanced laboratory networks and consolidated reference labs drive demand for high-throughput automation and integrated data platforms, while investments in infrastructure and a focus on scale encourage vendor partnerships that emphasize service and local support. In contrast, the Europe, Middle East & Africa region presents a heterogeneous picture: many markets pursue harmonized regulatory frameworks and centralized genomic initiatives, yet infrastructure variability and fragmented procurement practices require flexible, modular solutions that can operate across diverse clinical contexts.

Meanwhile, Asia-Pacific demonstrates rapid adoption of automation in both centralized and decentralized testing environments, supported by strong domestic manufacturing capabilities in several markets and a growing emphasis on genomic medicine. These regional differences affect vendor go-to-market strategies, with successful suppliers tailoring distribution models, validation packages, and training services to local regulatory regimes and laboratory maturity levels. Consequently, regional insight must inform any commercialization plan, supply chain design, and customer engagement approach to ensure compatibility with local clinical workflows and procurement expectations.

Key company strategies reveal how platform integration, modular architectures, service excellence, and regulatory expertise differentiate competitive positioning and vendor selection

Leading companies in the molecular diagnostics automation space follow differentiated strategies that reflect technological strengths, service models, and route-to-market choices. Some vendors prioritize platform-based approaches that integrate instruments, consumables, and software to lock in long-term recurring revenue and ensure validated end-to-end workflows. Others compete on modularity and open-architecture systems that appeal to customers seeking flexibility and the ability to mix and match instruments from multiple suppliers. Across both approaches, investments in connectivity, remote monitoring, and lifecycle services increasingly determine competitive positioning.

Moreover, successful organizations emphasize regulatory expertise and global service footprints to reduce adoption friction for customers operating across jurisdictions. Partnerships with laboratory networks and strategic alliances with software providers accelerate time-to-implementation and broaden addressable use cases. Additionally, several companies leverage scale in manufacturing and distribution to improve supply reliability and absorb logistical challenges. For buyers, this translates into evaluating suppliers not only on instrument performance but also on their ability to deliver validated workflows, dependable service, and long-term roadmap alignment that supports evolving clinical needs.

Actionable recommendations for laboratory executives and vendors to align automation investments with clinical priorities, supply chain resilience, workforce transformation, and interoperability goals

Industry leaders should adopt a proactive posture to capture the benefits of automation while managing risk across clinical, operational, and commercial domains. First, align automation investments with clinical priorities by piloting solutions that address high-volume, high-impact assays and that demonstrate reproducible gains in turnaround time and error reduction. Simultaneously, develop workforce transition plans that reskill laboratory staff for automation oversight, data interpretation, and instrument maintenance to maximize return on technology investments.

Second, strengthen supply chain resilience through multi-source sourcing strategies, regionally diversified inventory, and contractual terms that account for tariff and logistics variability. Third, prioritize interoperability and data standards when procuring instruments and software to facilitate integration with laboratory information systems and to enable scalable analytics. Fourth, negotiate service-level agreements that include remote diagnostics, preventative maintenance, and clear escalation pathways to minimize downtime. Finally, pursue strategic partnerships with vendors that offer validated workflows and training programs, thereby reducing deployment risk and accelerating clinical adoption. By combining these tactical moves into a cohesive automation roadmap, organizations can sustain operational continuity while unlocking higher-value molecular diagnostics capabilities.

A rigorous mixed-methods research approach combining stakeholder interviews, technical validation, secondary literature, and scenario analysis to produce reliable, application-oriented insights

The research methodology synthesizes primary and secondary evidence, qualitative interviews, and technical validation to ensure robust, actionable insights. Primary research included structured interviews with laboratory directors, procurement leaders, and senior technical staff across clinical, hospital, reference, pharmaceutical, and research laboratory settings to capture firsthand perspectives on automation drivers, barriers, and implementation outcomes. These interviews informed deeper analysis of workflow requirements, staffing implications, and technology selection criteria.

Secondary research drew on peer-reviewed literature, regulatory guidance, company technical documentation, and supply chain data to validate product capabilities, integration standards, and service models. Integrative analysis used cross-validation techniques to reconcile stakeholder testimony with documented performance characteristics and published case studies. In addition, scenario analysis examined procurement and tariff sensitivities, while technology maturity assessments evaluated readiness levels for different automation modalities. Throughout, quality control processes ensured transparency in data sources and reproducibility of conclusions, enabling decision-makers to apply findings with confidence in operational planning and vendor selection.

Concluding synthesis emphasizing how strategic automation adoption transforms diagnostic capability, operational resilience, and clinical value delivery across laboratory environments

Automation in molecular diagnostics has moved from a niche efficiency play to a central element of laboratory strategy, affecting how organizations deliver diagnostics, manage risk, and compete in value-based healthcare settings. Integrated automation reduces manual variability, improves throughput, and enables complex genomic workflows that were previously constrained by labor and instrumentation fragmentation. As a result, laboratories that adopt automation strategically gain advantages in turnaround time, reproducibility, and the ability to scale novel assays into routine practice.

Looking ahead, the interplay between technology providers, laboratories, and regulatory frameworks will determine the pace and pattern of adoption. Organizations that prioritize interoperability, supply chain resilience, and workforce readiness will navigate disruptions more effectively and capitalize on opportunities to extend services and enter new clinical domains. In sum, automation represents both a technological enabler and a business lever; when applied thoughtfully, it transforms laboratory capability and supports higher-quality patient care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of high-throughput automation systems in next-generation sequencing workflows to reduce turnaround times
  • 5.2. Adoption of robotic sample preparation platforms for multiplex PCR assays in decentralized diagnostic labs
  • 5.3. Implementation of AI-driven data analysis pipelines for real-time interpretation of molecular diagnostic results
  • 5.4. Development of modular lab-on-a-chip devices enabling automated point-of-care nucleic acid testing in remote settings
  • 5.5. Standardization of automated liquid handling protocols to enhance reproducibility across multi-site molecular testing networks
  • 5.6. Expansion of closed system automation combining sample extraction and qPCR to minimize contamination risk and operator error

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Automation in the Molecular Diagnostics Market, by Product Type

  • 8.1. Consumables & Reagents
    • 8.1.1. Microarray Chips
    • 8.1.2. Ngs Library Prep Kits
    • 8.1.3. Pcr Kits
  • 8.2. Instruments
    • 8.2.1. Microarray Systems
    • 8.2.2. Ngs Instruments
    • 8.2.3. Pcr Instruments
  • 8.3. Software & Services
    • 8.3.1. Data Analysis Software
    • 8.3.2. Integration Services
    • 8.3.3. Managed Services

9. Automation in the Molecular Diagnostics Market, by End User

  • 9.1. Clinical Laboratories
  • 9.2. Hospital Laboratories
  • 9.3. Pharmaceutical & Biotechnology Companies
  • 9.4. Reference Laboratories
  • 9.5. Research Laboratories

10. Automation in the Molecular Diagnostics Market, by Technology

  • 10.1. Microarrays
  • 10.2. Ngs
  • 10.3. Pcr

11. Automation in the Molecular Diagnostics Market, by Automation Level

  • 11.1. Fully Automated Systems
  • 11.2. Semi-Automated Systems
  • 11.3. Walkaway Automation

12. Automation in the Molecular Diagnostics Market, by Application

  • 12.1. Cardiovascular Diseases
  • 12.2. Genetic Testing
  • 12.3. Infectious Disease
  • 12.4. Oncology
  • 12.5. Women's Health

13. Automation in the Molecular Diagnostics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Automation in the Molecular Diagnostics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Automation in the Molecular Diagnostics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. F. Hoffmann-La Roche Ltd
    • 16.3.2. Thermo Fisher Scientific Inc.
    • 16.3.3. Danaher Corporation
    • 16.3.4. Abbott Laboratories
    • 16.3.5. QIAGEN N.V.
    • 16.3.6. bioMerieux SA
    • 16.3.7. Bio-Rad Laboratories, Inc.
    • 16.3.8. Siemens Healthineers AG
    • 16.3.9. PerkinElmer, Inc.
    • 16.3.10. Agilent Technologies, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION LEVEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION LEVEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAY CHIPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAY CHIPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAY CHIPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAY CHIPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAY CHIPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAY CHIPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY NGS LIBRARY PREP KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY NGS LIBRARY PREP KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY NGS LIBRARY PREP KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY NGS LIBRARY PREP KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY NGS LIBRARY PREP KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY NGS LIBRARY PREP KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAY SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAY SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAY SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAY SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAY SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAY SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY NGS INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY NGS INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY NGS INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY NGS INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY NGS INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY NGS INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INTEGRATION SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INTEGRATION SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INTEGRATION SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INTEGRATION SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INTEGRATION SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INTEGRATION SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MANAGED SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MANAGED SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MANAGED SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MANAGED SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MANAGED SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MANAGED SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CLINICAL LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CLINICAL LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CLINICAL LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CLINICAL LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CLINICAL LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CLINICAL LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY HOSPITAL LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY HOSPITAL LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY HOSPITAL LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY HOSPITAL LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY NGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY NGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY NGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY NGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY NGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY NGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION LEVEL, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION LEVEL, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY FULLY AUTOMATED SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY FULLY AUTOMATED SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY FULLY AUTOMATED SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY FULLY AUTOMATED SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY FULLY AUTOMATED SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY FULLY AUTOMATED SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SEMI-AUTOMATED SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SEMI-AUTOMATED SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SEMI-AUTOMATED SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SEMI-AUTOMATED SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SEMI-AUTOMATED SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SEMI-AUTOMATED SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY WALKAWAY AUTOMATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY WALKAWAY AUTOMATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY WALKAWAY AUTOMATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY WALKAWAY AUTOMATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY WALKAWAY AUTOMATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY WALKAWAY AUTOMATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY WOMEN'S HEALTH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY WOMEN'S HEALTH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY WOMEN'S HEALTH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY WOMEN'S HEALTH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY WOMEN'S HEALTH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY WOMEN'S HEALTH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 197. AMERICAS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 199. AMERICAS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION LEVEL, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION LEVEL, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. NORTH AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 216. NORTH AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2024 (USD MILLION)
  • TABLE 218. NORTH AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2025-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 220. NORTH AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 222. NORTH AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION LEVEL, 2018-2024 (USD MILLION)
  • TABLE 224. NORTH AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION LEVEL, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. LATIN AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 230. LATIN AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 232. LATIN AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 234. LATIN AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2024 (USD MILLION)
  • TABLE 236. LATIN AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2025-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 238. LATIN AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION LEVEL, 2018-2024 (USD MILLION)
  • TABLE 242. LATIN AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION LEVEL, 2025-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 244. LATIN AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION LEVEL, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION LEVEL, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE